Completed PHASE2 INTERVENTIONAL 2-arm NCT01357109

Effect of Bosentan on Endothelial Function in Patients With Type 2 Diabetes (BANDY)

Effect of Bosentan on Macro- and Microvascular Function in Patients With Type 2 Diabetes

Sponsor: Actelion

Updated 4 times since 2017 Last updated: May 18, 2011 Started: Nov 30, 2007 Primary completion: Apr 30, 2010 Completion: Jan 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01357109, this PHASE2 trial focuses on Type 2 Diabetes Mellitus and remains completed. Sponsored by Actelion, it has been updated 4 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2017 — Jan 2021 [monthly]

Completed PHASE2

First recorded

Nov 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Actelion
Karolinska Institutet
Swedish Heart Lung Foundation
The Swedish Research Council

Data source: Karolinska Institutet

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Stockholm, Sweden